From Wikipedia, the free encyclopedia
Jump to: navigation, search
Systematic (IUPAC) name
Clinical data
Trade names Sivextro
Pregnancy cat.
Legal status
Routes Oral,IV
Pharmacokinetic data
Bioavailability 91%
Protein binding 70-90%
Half-life 12 hours
Excretion Feces
CAS number 856866-72-3 N
ATC code None
ChemSpider 9409096 YesY
KEGG D09685 YesY
Chemical data
Formula C17H15FN6O3 
Mol. mass 370.338 g/mol
 N (what is this?)  (verify)

Tedizolid (formerly torezolid[1]), marketed under the trade name Sivextro, is an oxazolidinone drug being developed by Cubist Pharmaceuticals following acquisition of Trius Therapeutics (originator: Dong-A Pharmaceuticals) for complicated skin and skin-structure infections (cSSSI), including those caused by methicillin-resistant Staphylococcus aureus (MRSA).[2]

The prodrug tedizolid is called "TR-701", while the active moiety is called "TR-700".[3][4]

Clinical trials[edit]

As of July 2012, tedizolid had completed one phase III trial, with another one under way.[5] Both trials compare a six-day regimen of tedizolid 200 mg once-daily against a ten-day regimen of linezolid 600 mg twice-daily. The results of the pivotal phase III trial ESTABLISH 1 were published in February 2013. It met the primary and both secondary endpoints.[6]

Tedizolid has been approved by the FDA on June 20, 2014 for the treatment of methicillin-resistant S. aureus skin infections. It can be taken both orally and given via IV injection.[7] Sivextro is the second treatment approved by the Food and Drug Administration under the new federal Generating Antibiotic Incentives Now law, known as the GAIN Act. That law gives drug makers priority review and an additional five years of market exclusivity in order to spur the development of new antibiotics to fight the rise of drug-resistant “superbugs.”


  1. ^ "Trius grows as lead antibiotic moves forward". 31 Oct 2011. 
  2. ^ "Trius Completes Enrollment In Phase 2 Clinical Trial Evaluating Torezolid (TR-701) In Patients With Complicated Skin And Skin Structure Infections". Jan 2009. 
  3. ^ PMID 19528279 In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent.
  4. ^ PMID 19218276 TR-700 in vitro activity against and resistance mutation frequencies among Gram-positive pathogens.
  5. ^ http://clinicaltrials.gov/ct2/results?flds=Xf&flds=a&flds=b&term=tedizolid&phase=2&fund=2&show_flds=Y
  6. ^ New MRSA treatment
  7. ^ Weisman, Robert (June 20, 2014). "FDA approves new Cubist antibiotic". Boston Globe.